Themis Medicare Ltd.

NSE: THEMISMED BSE: 530199 SECTOR: Pharmaceuticals & Drugs  15k   42   4

1468.55
-8.00 (-0.54%)
NSE: 02 Jun 03:40 PM

Price Summary

Today's High

₹ 1498.7

Today's Low

₹ 1464.4

52 Week High

₹ 1700

52 Week Low

₹ 686.45

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1351.47 Cr.

Enterprise Value

1403.54 Cr.

No. of Shares

0.92 Cr.

P/E

31.22

P/B

5.45

Face Value

₹ 10

Div. Yield

0.34 %

Book Value (TTM)

₹  269.54

CASH

26.49 Cr.

DEBT

78.55 Cr.

Promoter Holding

67.16 %

EPS (TTM)

₹  47.04

Sales Growth

71.07%

ROE

28.72 %

ROCE

31.27%

Profit Growth

131.24 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year71.07%
3 Year28.93%
5 Year12.74%

Profit Growth

1 Year131.24%
3 Year89.9%
5 Year33%

ROE%

1 Year28.72%
3 Year18.25%
5 Year10.5%

ROCE %

1 Year31.27%
3 Year20.34%
5 Year13.82%

Debt/Equity

0.3229

Price to Cash Flow

39.29

Interest Cover Ratio

10.5672244004741

CFO/PAT (5 Yr. Avg.)

1.09796293739839

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 67.16 23.51
Dec 2022 67.18 23.51
Sep 2022 67.18 23.51
Jun 2022 67.18 23.51
Mar 2022 67.18 23.51
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 89.9038304369013% for the Past 3 years.
  • The company has shown a good revenue growth of 28.9333851844914% for the Past 3 years.
  • Company has been maintaining healthy ROCE of 20.3381308668922% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 10.5672244004741.
  • Company’s PEG ratio is 0.238390542588669.
  • The company has an efficient Cash Conversion Cycle of 50.6136537533152 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.09796293739839.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 45.0347754341422.

 Limitations

  • Promoter pledging is high as 23.51%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 79.8 94.44 91 88.78 80.11
Total Expenditure 65.37 74.08 69.66 73.51 69.62
Operating Profit 14.42 20.36 21.34 15.27 10.49
Other Income 1.84 0.69 1.97 5.9 2.95
Interest 1.93 2.26 2.37 2.23 2.71
Depreciation 2.39 2.46 2.56 2.67 2.8
Exceptional Items 0 0 0 0 0
Profit Before Tax 11.95 16.33 18.38 16.27 7.93
Tax 4.39 4.69 4.85 4.19 1.89
Profit After Tax 7.55 11.63 13.53 12.09 6.04
Adjusted EPS (Rs) 8.21 12.65 14.71 13.14 6.57

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 209.5 184.11 201.59 230.67 394.61
Total Expenditure 184.35 181.54 165.91 180.79 298.96
Operating Profit 25.15 2.57 35.68 49.88 95.65
Other Income 3.52 2.69 3.47 3.62 6.54
Interest 11.87 11.82 12.88 12.71 8.77
Depreciation 7.41 7.98 8.27 8.55 9.48
Exceptional Items 0 0 0 0 0
Profit Before Tax 9.4 -14.53 18.01 32.25 83.94
Tax 0.1 -1.84 2.09 5.63 22.38
Net Profit 9.29 -12.7 15.91 26.62 61.56
Adjusted EPS (Rs.) 10.12 -13.83 17.32 28.97 66.91

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 9.18 9.18 9.19 9.19 9.2
Total Reserves 146.85 134.16 150.13 176.61 234.28
Borrowings 11.5 9.35 11.85 22.2 23.88
Other N/C liabilities -4.78 -6.64 -4.35 2.13 6.89
Current liabilities 124.91 146.65 154.79 128.27 123.48
Total Liabilities 287.66 292.7 321.61 338.4 397.74
Assets
Net Block 125.89 123.4 116.31 133.1 144
Capital WIP 2.47 2.45 7.54 2.47 2.56
Intangible WIP 0 0 0 0 0
Investments 11.01 11.02 10.96 10.98 11.01
Loans & Advances 2.37 2.67 2.91 2.83 6.9
Other N/C Assets 2.3 2.45 2.62 2.31 3.84
Current Assets 143.62 150.7 181.28 186.72 229.42
Total Assets 287.66 292.7 321.61 338.4 397.74
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 9.4 -14.53 18.01 32.25 83.94
Adjustment 16.99 19.03 18.22 17.13 11.1
Changes in Assets & Liabilities -19.15 6.77 -35.65 7.52 -42.57
Tax Paid 0.65 -0.3 -0.24 0.08 -18.07
Operating Cash Flow 7.88 10.97 0.33 56.98 34.39
Investing Cash Flow -0.07 -3.79 -5.46 -15.65 -15.58
Financing Cash Flow -9.11 -9.94 6.72 -25.65 -17.55
Net Cash Flow -1.3 -2.75 1.6 15.68 1.26

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 67.18 67.18 67.18 67.18 67.16
vividhmargi invest... - - - - -
vividhmargi invest... 15.79 15.79 15.79 15.79 15.79
gedeon richter inv... 9.61 9.61 9.61 9.61 9.61
gedeon richter inv... - - - - -
gedeon richter inv... 9.61 9.61 9.61 9.61 9.61
dinesh shantilal p... 9.48 9.48 9.48 9.48 9.48
vividh distributor... 7.78 7.78 7.78 7.78 7.78
vividh distributor... - - - - -
jayshree d patel 7.26 7.26 7.26 7.26 7.26
sachin dinesh patel 6.00 6.00 6.00 6.00 5.99
reena s patel 4.04 4.04 4.04 4.04 4.04
themis distributor... 2.98 2.98 2.98 2.98 2.98
themis distributor... - - - - -
nysha rupen choksi 1.28 1.28 1.28 1.28 1.28
anay rupen choksi 1.28 1.28 1.28 1.28 1.28
dinesh s patel huf 1.07 1.07 1.07 1.07 1.07
shantilal dahyabha... - 0.61 - - -
shantilal dahyabha... - - 0.61 - -
shantilal dahyabha... 0.61 - - 0.61 0.61
shantilal dahyabha... - - - - -
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 32.82 32.82 32.82 32.82 32.84
anuj anantrai sheth 4.89 4.89 4.89 4.89 4.89
zafar ahmadullah 1.76 1.76 2.34 2.34 2.34
zafar ahmadullah - - - - -
za capital service... 1.58 1.58 1.58 1.58 1.61
altitude investmen... - - - - -
jewels advisory se... 1.09 1.09 - - -
hirak leasing and ... - - 1.09 - -
jagat lodha - - - 1.05 1.05
investor education... - - 0.34 - 0.34
investor education... - - - 0.34 -
iepf 0.34 0.34 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Themis Medicare informs about investors’ presentation15 May 2023, 10:51AM Themis Medicare - Quaterly Results13 May 2023, 4:15PM Themis Medicare - Quaterly Results13 May 2023, 4:15PM Themis Medicare - Quaterly Results13 May 2023, 4:15PM Themis Medicare informs about compliance certificate17 Apr 2023, 4:03PM Themis Medicare informs about press release 17 Feb 2023, 3:31PM Themis Medicare gets DCGI’s nod to import, market Remifentanil 1mg/2mg Powder for Injection17 Feb 2023, 2:58PM Themis Medicare informs about analyst meet 17 Feb 2023, 10:33AM Themis Medicare informs about loss of share certificate9 Feb 2023, 5:14PM Themis Medicare - Quaterly Results3 Feb 2023, 1:44PM Themis Medicare - Quaterly Results3 Feb 2023, 1:44PM Themis Medicare - Quaterly Results3 Feb 2023, 1:44PM Themis Medicare informs about loss of share certificate2 Feb 2023, 2:52PM Themis Medicare informs about certificate11 Jan 2023, 3:11PM Themis Medicare launches novel transdermal Estradiol spray Lenzetto in Indian market4 Jan 2023, 9:35AM Themis Medicare informs about loss of share certificate28 Dec 2022, 3:24PM Themis Medicare informs about closure of trading window26 Dec 2022, 5:25PM Themis Medicare informs about cancellation of analyst meet 19 Dec 2022, 12:26PM Themis Medicare informs about newspaper publication 13 Dec 2022, 9:54AM Themis Medicare informs about notice of postal ballot and e-voting9 Dec 2022, 4:06PM Themis Medicare informs about transcript of conference call 21 Nov 2022, 4:58PM Themis Medicare gets nod to transfer API business to subsidiary8 Nov 2022, 10:44AM Themis Medicare - Quaterly Results7 Nov 2022, 7:37PM Themis Medicare - Quaterly Results7 Nov 2022, 7:37PM Themis Medicare informs about typographical error in board meeting intimation 31 Oct 2022, 10:58AM Themis Medicare partners with NFL Biosciences to develop NFL-1017 Oct 2022, 10:50AM Themis Medicare informs about analyst meet 22 Sep 2022, 10:54AM Themis Medicare informs about voting results of AGM21 Sep 2022, 12:20PM Themis Medicare informs about appointment of statutory auditors20 Sep 2022, 1:30PM Themis Medicare informs about analyst meet15 Sep 2022, 10:10AM Themis Medicare informs about annual report27 Aug 2022, 12:39PM Themis Medicare informs about annual report27 Aug 2022, 11:50AM Themis Medicare informs about newspaper publication23 Aug 2022, 4:29PM Themis Medicare informs about outcome of board meeting28 Jul 2022, 3:22PM Themis Medicare - Quaterly Results28 Jul 2022, 2:17PM Themis Medicare - Quaterly Results28 Jul 2022, 2:17PM Themis Medicare - Quaterly Results28 Jul 2022, 2:17PM Themis Medicare - Quaterly Results21 May 2022, 3:49PM Themis Medicare - Quaterly Results21 May 2022, 3:49PM Themis Medicare - Quaterly Results21 May 2022, 3:49PM Themis Medicare gets DCGI’s add on approval for ‘Viralex’18 May 2022, 3:35PM Themis Medicare informs about change in directorate28 Mar 2022, 3:02PM Themis Medicare informs about updates21 Mar 2022, 12:45PM Themis Medicare gets DCGI nod for antiviral drug ‘Viralex’21 Mar 2022, 12:22PM Themis Medicare gets approval for immunomodulatory antiviral drug ‘VIRALEX’4 Mar 2022, 9:20AM Themis Medicare - Quaterly Results11 Feb 2022, 2:41PM Themis Medicare - Quaterly Results11 Feb 2022, 2:41PM Themis Medicare - Quaterly Results11 Feb 2022, 2:41PM Themis Medicare incorporates new subsidiary company24 Dec 2021, 11:28AM Themis Medicare informs about analyst meet28 Sep 2021, 2:24PM

Themis Medicare Stock Price Analysis and Quick Research Report. Is Themis Medicare an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Themis Medicare and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 34.3938 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Themis Medicare has a Debt to Equity ratio of 0.3229 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Themis Medicare , the EPS growth was 130.945584453687 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Themis Medicare has OPM of 24.2392251062494 % which is a good sign for profitability.
     
  • ROE: Themis Medicare have a healthy ROE of 28.7195907258756 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Themis Medicare

X